Title |
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study
|
---|---|
Published in |
European Heart Journal, March 2012
|
DOI | 10.1093/eurheartj/ehs059 |
Pubmed ID | |
Authors |
Deepak L. Bhatt, Guillaume Paré, John W. Eikelboom, Katy L. Simonsen, Eileen S. Emison, Keith A.A. Fox, Ph. Gabriel Steg, Gilles Montalescot, Nihar Bhakta, Werner Hacke, Marcus D. Flather, Koon-Hou Mak, Patrice Cacoub, Mark A. Creager, Peter B. Berger, Steven R. Steinhubl, Gurunathan Murugesan, Shamir R. Mehta, Kandice Kottke-Marchant, A. Michael Lincoff, Eric J. Topol |
Abstract |
Clinical trials have established the value of clopidogrel therapy in a wide spectrum of patients with cardiovascular diseases. Both loss- and gain-of-function single nucleotide variants of CYP2C19 genes have been identified that affect clopidogrel metabolism and anti-platelet response. We sought to determine the impact of CYP2C19 polymorphisms on ischaemic and bleeding events. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 1% |
Sweden | 1 | 1% |
Singapore | 1 | 1% |
Canada | 1 | 1% |
Unknown | 79 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 11 | 13% |
Student > Bachelor | 11 | 13% |
Student > Ph. D. Student | 8 | 10% |
Researcher | 8 | 10% |
Student > Postgraduate | 7 | 8% |
Other | 20 | 24% |
Unknown | 18 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 37 | 45% |
Pharmacology, Toxicology and Pharmaceutical Science | 8 | 10% |
Nursing and Health Professions | 4 | 5% |
Biochemistry, Genetics and Molecular Biology | 3 | 4% |
Agricultural and Biological Sciences | 2 | 2% |
Other | 3 | 4% |
Unknown | 26 | 31% |